{"organizations": [], "uuid": "1c86f0145003a5defe8e8184f370d4631e6c13b2", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-sage-therapeutics-submits-new-drug/brief-sage-therapeutics-submits-new-drug-application-to-u-s-fda-for-intravenous-brexanolone-in-the-treatment-of-postpartum-depression-idUSASC09WQX", "country": "US", "domain_rank": 408, "title": "Sage Therapeutics Submits New Drug Application To U.S. FDA For Intravenous Brexanolone In The Treatment Of Postpartum Depression", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.954, "site_type": "news", "published": "2018-04-23T19:15:00.000+03:00", "replies_count": 0, "uuid": "1c86f0145003a5defe8e8184f370d4631e6c13b2"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-sage-therapeutics-submits-new-drug/brief-sage-therapeutics-submits-new-drug-application-to-u-s-fda-for-intravenous-brexanolone-in-the-treatment-of-postpartum-depression-idUSASC09WQX", "ord_in_thread": 0, "title": "Sage Therapeutics Submits New Drug Application To U.S. FDA For Intravenous Brexanolone In The Treatment Of Postpartum Depression", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "treatment of postpartum depression  sage therapeutics inc", "sentiment": "neutral"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Market News  15 AM / Updated 8 minutes ago BRIEF-Sage Therapeutics Submits New Drug Application To U.S. FDA For Intravenous Brexanolone In The Treatment Of Postpartum Depression Reuters Staff 1 Min Read \nApril 23 (Reuters) - SAGE Therapeutics Inc: \n* SAGE THERAPEUTICS SUBMITS NEW DRUG APPLICATION TO U.S. FDA FOR INTRAVENOUS BREXANOLONE IN THE TREATMENT OF POSTPARTUM DEPRESSION \n* SAGE THERAPEUTICS SUBMITS NEW DRUG APPLICATION TO U.S. FDA FOR INTRAVENOUS BREXANOLONE IN THE TREATMENT OF POSTPARTUM DEPRESSION \n* SAGE THERAPEUTICS - NDA SUBMISSION SUPPORTED BY DATA FROM HUMMINGBIRD PROGRAM Source text for Eikon: Further company coverage:", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-23T19:15:00.000+03:00", "crawled": "2018-04-23T14:28:19.010+03:00", "highlightTitle": ""}